Full Press Release Details
Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus
VICTORIA, British Columbia--(BUSINESS WIRE)--September 17, 2015--Aurinia
Pharmaceuticals Inc. ("Aurinia" or the "Company"),
(NASDAQ:AUPH)(TSX:AUP) announces that it has filed a preliminary short
form base shelf prospectus (the "Shelf Prospectus") with the securities
commissions in each of the provinces of Ontario, Alberta and British
Columbia in Canada, and a corresponding shelf registration statement on
Form F-10 with the U.S. Securities and Exchange Commission (the "SEC")
under the U.S./Canada Multijurisdictional Disclosure System.
The Shelf Prospectus and corresponding shelf registration statement,
when made final or effective, will allow Aurinia to offer up to
US$250,000,000 of common shares, warrants and subscription receipts or
any combination thereof during the 25-month period that the Shelf
Prospectus is effective. The Shelf Prospectus is intended to give
Aurinia the capability to access new capital from time to time. The
amount and timing of any future offerings will be based on the Company's
financial requirements and market conditions at the time. The Company
has no immediate intention to undertake an offering.
The specific terms of any future offering under the Shelf Prospectus
will be established at the time of such offering. At the time any of the
securities covered by the Shelf Prospectus are offered for sale, a
prospectus supplement containing specific information about the terms of
such offering will be filed with applicable Canadian securities
regulatory authorities and the SEC.
The shelf registration statement filed today with the SEC has not yet
become effective. No securities may be sold, nor may offers to buy be
accepted, prior to the time the registration statement becomes
effective. This news release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any jurisdiction in which an offer, solicitation or sale
would be unlawful prior to registration or qualifications under the
securities laws of any such jurisdiction.
A copy of the Shelf Prospectus can be found on SEDAR at www.sedar.com
and a copy of the corresponding shelf registration statement can be
found on EDGAR at www.sec.gov or may be obtained upon request to
Aurinia's Investor Relations Department, #1203 - 4464 Markham Street,
Victoria, British Columbia, Canada, V8Z 7X8.
Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is
currently in the recruitment and enrollment phase of its Phase 2b
clinical trial to evaluate the efficacy of its drug, voclosporin, as a
treatment for lupus nephritis (LN). LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Forward-Looking Statement Disclaimer
in this news release contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including without
limitation statements containing the words "believe", "may", "plan",
"will", "estimate", "continue", "anticipate", "intend", "expect" and
similar expressions. Forward-looking statements in this news release
include statements regarding the Shelf Prospectus and corresponding
shelf registration statement being cleared by the applicable Canadian
securities regulatory authorities and Aurinia's intention to take
advantage of financing opportunities when market conditions are
favourable. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada, Europe, and the other regions in which we operate; not
receiving the regulatory approvals, including the further approvals that
may be sought from securities regulatory authorities or the SEC, on the
timelines required or at all, that the prevailing market price of our
securities may make a prospectus offering in respect of such securities
unattractive to Aurinia as well as those factors discussed in or
referred to under the heading "Risk Factors" in Aurinia's Annual Report
on Form 20-F for the year ended December 31, 2014 which is available
under Aurinia's profile on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov. Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their
entirety by this cautionary statement. All forward-looking statements
and information made herein are based on our current expectations and we
undertake no obligation to revise or update such forward-looking
statements and information to reflect subsequent events or
circumstances, except as required by law.
Stephen Zaruby, 250-708-4293
& Chief Executive Officer
Michael R. Martin, 250-708-4272